Lirum Therapeutics (Lirum Therapeutics) COGS-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics COGS-to-Revenue?

Lirum Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was $0.00 Mil.

Lirum Therapeutics's COGS to Revenue for the three months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Lirum Therapeutics's Gross Margin % for the three months ended in Dec. 2023 was N/A%.

Lirum Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Lirum Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics COGS-to-Revenue Chart

Lirum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

COGS-to-Revenue

Lirum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
COGS-to-Revenue	-	-	-	-	-

Lirum Therapeutics COGS-to-Revenue Calculation

Lirum Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Lirum Therapeutics's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Lirum Therapeutics (NAS:LRTX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Lirum Therapeutics's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Lirum Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Lirum Therapeutics (Lirum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

590 Madison Avenue, 21st Floor, New York, NY, USA, 10022

Website

https://www.lirumtx.com

Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines